Skip to main content
  • Saved

Commented on 's Post

Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients

Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients

Source :

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436334/

Proc Natl Acad Sci U S A. 2022 Aug 30; 119(35): e2207531119. Rebecca Evans, a , 1 , 2 Haruhide Kimura, b , 1 Robert Alexander, a , 2 Ceri H. Davies, b Hélène Faessel, a Deborah S.


Relevance: Narcolepsy type 1 (NT1) is a sleep disorder caused by a loss of orexinergic neurons. Narcolepsy type 2 (NT2) is heterogeneous; affected individuals typically have normal orexin levels. Following evaluation in mice, the effects of the orexin 2 receptor (OX2R)-selective agonist danavorexton were evaluated in single- and multiple-rising-dose studies in healthy adults, and in individuals with NT1 and NT2.

  • from Doctor Unite September 12, 2022
    Polypharmacy is often needed to address the various symptoms of NT1, but no current treatments directly address the loss of orexin